PHARMACOECONOMIC ANALYSIS OF TREATMENT USING DIRECT-ACTING ANTIVIRALS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C

Download full text PDF
DOI: https://doi.org/None
Issue: 
1
Year: 
2016

N.Z. Musina (1), PhD; A.G. Savilova (2), O.M. Korzinov 1 -I.M. Sechenov First Moscow State Medical University; 8, Trubetskaya St., Build. 2, Moscow 119991 2 -Moscow Institute of Physics and Technology; 9, Institutskiy Lane, Dolgoprudnyi, Moscow Region 141700

A comparative pharmacoeconomic analysis of treatment using antivirals (boceprevir, simeprevir, and telaprevir) was carried out in patients with genotype 1 chronic hepatitis C. The costs of drug therapy, correction of side effects, and medical services were studied. The data of clinical efficiency were based on the results of the clinical trials of the medications. Cost-effectiveness analysis revealed the most appropriate pharmacoeconomic treatments for patients who had been previously untreated or treated, partially responded or had a recurrence after previous therapy. Standard dual therapy with pegylated interferons in combination with ribavirin, which showed maximum cost-effectiveness, proved to be least preferred.
Keywords: 
chronic hepatitis C
direct-acting antivirals
pharmacoeconomic analysis
References: 
  1. http://www.who.int/mediacentre/factsheets/fs164/ru/
  2. http://rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php?ELEMENT_ID=2938
  3. Rekomendacii po diagnostike i lecheniyu vzroslyh bol`nyh gepatitom S 2013 g. http://www.hcv.ru/deseas/treat/hcv_reko-mend_2013.html (Guidance for hepatitis C treatment in adults 2013).
  4. Yushhuk N.D., Znoyko O.O., Dudina K.R., Shut`ko S.A., Kozina A.N., Safiullina N.H., Fedoseeva N.V., Belyy P.A., Lugovskih E.A., Ogarev V.V., Rahmanova A.G., Hubutiya M.Sh., Yakushechkina N.A., Pimenov N.N., Chulanov V.P., Chesnokov E.V. Ocenka social`no-e`konomicheskogo bremeni gepatita S v Rossiyskoy Federacii. Epidemiology and vaccinal prevention., 2013;2(69): 18-33. [Jushhuk N.D., Znojko O.O., Dudina K.R., Shut’ko S.A., Kozina A.N., Safiullina N.H., Fedoseeva N.V., Belyj P.A., Lugovskih E.A., Ogarev V.V., Rahmanova A.G., Hubutija M.Sh., Jakushechkina N.A., Pimenov N.N., Chulanov V.P., Chesnokov E.V. Assessment of the Socio-Economic Burden of Hepatitis C in the Russian Federation. Epidemiology and vaccinalprevention., 2013. 2 (69):18–33] (in Russian).
  5. World Health Organization guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
  6. Drummond M.F., McGuire A. Economic evaluation of health care. Merging theory with practice. Oxford. Univ. Press., 2007; 72–78.
  7. Drummond M.F., Sculpher M.J., Torrance G.W., O’Brien B.J. Methods for the economic evaluation of health care programmes. Oxford. Univ. Press., 2005; 8–10.
  8. Jacobson I.M., Mc Hutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P.Telaprevir for previously untreated chronic hepatitis C virus infection.N. Engl. J. Med., 2011; 364(25): 2405–2416.
  9. Zeuzem S., Andreone P., Pol S. et al.Telaprevir for retreatment of HCV infection. N. Engl. J. Med., 2011; 364: 2417–2428.
  10. Poordad F., Mc Cone J.Jr., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011; 364 (13): 1195–1206.
  11. Bacon B., Gordon S., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011; 364: 1207–1217.
  12. Flamm S.L., Lawitz E., Jacobson I., Bourlière M., Hezode C. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chron-ic hepatitis C genotype 1 infection. Clin.Gastroenterol.Hepatol., 11: 81–7.
  13. Vierling, J., Zeuzem, S., Poordad, F., Bronowicki, J., Manns, M., Bacon, B. Safety and efficacy of boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with com-pensated cirrhosis: a meta-analysis of five phase 3 clinical trials. J.Hepatol., 2013; 58: 576–577.
  14. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M.Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; (pub-lished online June 4.)http://dx.doi.org/10.1016/S0140-6736(14)60494-3.
  15. Manns M., Marcellin P., Poordad F. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chron-ic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet., 2014; 384 (9941): 414–426.
  16. Forns X., Lawitz E., Zeuzem E. et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology., 2014; 146 (7): 1669–1679.
  17. Mc Hutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009; 361 (6): 580–593.
  18. Shiffman M.L. Retreatment of HCV Non-responders with peginter-feron and ribavirin: Results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology, 2002; 36: 295.
  19. Boceprevir for the treatment of genotype 1 chronic hepatitis C NICE technology appraisal guidance [TA253]
  20. http://grls.rosminzdrav.ru/pricelims.aspx
  21. . http://moskva.003ms.ru/price.aspx
  22. http://www.mma.ru/service/
  23. Bueverov A.O. Profilaktika i korrekciya gematologicheskih pobochnyh e`ffektov protivovirusnoy terapii hronicheskogo gepatita S. RZhGGK, 2009; 19 (3): 76–81. [Bueverov A.O. Treatment and prophylaxis of hematological side effects of chronic hepatitis C antiviral therapy. RZhGGK, 2009; 19 (3): 76–81].
  24. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis: safety management in clinical practice. Liver International, 32 (suppl 1): 32–38.